Skip to main content
Figure 3 | Cardiovascular Diabetology

Figure 3

From: Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

Figure 3

Individual levels of a) triglyceride, b) triglyceride (normalized), c) high-density lipoprotein cholesterol, and d) apolipoprotein A-I in monkeys given aleglitazar 0.03 mg/kg per day. The final day of dosing at 0.03 mg/kg per day aleglitazar (labeled in the figures as day 42), due to scheduling needs, ranged across monkeys from 44 to 46 days.

Back to article page